Healthcare costs for MS treatment and the rate of relapse occurrence, of 1-point EDSS progression, of reaching of EDSS 4.0, of reaching of EDSS 6.0, and of SP conversion.

Healthcare costs for DMT administration and management before the specific endpoint was reached (considered as continuous variables), have been associated with the rate of relapse occurrence, of 1-point disability progression, of reaching of EDSS 4.0, of reaching of EDSS 6.0, and of SP conversion during the follow-up period. P-values, hazard ratios (HR), and 95% confidence intervals (95%CI) are shown from time varying Cox regression models, subsequently adjusted for age, gender, disease duration, and baseline EDSS.